Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

ClinicalTrials.gov ID: NCT00002766

Public ClinicalTrials.gov record NCT00002766. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Trial Comparing ARA-C/High-Dose Mitoxantrone ("ALL-2') to A Standard Vincristine/Prednisone Based Regimen ('L-20') as Induction Therapy For Adult Patients With Acute Lymphoblastic Leukemia (ALL): The ALL-4 Protocol

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia, lymphoblastic lymphoma, or chronic myelogenous leukemia. PURPOSE: This randomized phase III trial is studying two different chemotherapy regimens and comparing them to see how well they work in treating adults with acute lymphoblastic leukemia, lymphoblastic lymphoma, or chronic myelogenous leukemia.

Study identification

NCT ID: NCT00002766
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Enrollment: 170 participants

Conditions and interventions

Conditions

Interventions

Biological · Drug · Radiation

Eligibility (public fields only)

Age range: 18 Years to 120 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 1996 (Type not available)
Primary completion: Sep 2011 (Actual)
Completion: Sep 2011 (Actual)
Last update posted: Feb 22, 2016

1996 – 2011

United States locations

U.S. sites: 7
U.S. states: 5
U.S. cities: 7

Facility	City	State	ZIP	Site status
Jonsson Comprehensive Cancer Center, UCLA	Los Angeles	California	90095-1678	—
Stanford Cancer Center at Stanford University Medical Center	Stanford	California	94305-5750	—
Winship Cancer Institute of Emory University	Atlanta	Georgia	30322	—
Memorial Sloan-Kettering Cancer Center	New York	New York	10021	—
New York Medical College	Valhalla	New York	10595	—
Duke Comprehensive Cancer Center	Durham	North Carolina	27710	—
Cleveland Clinic Taussig Cancer Center	Cleveland	Ohio	44195	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00002766, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 22, 2016 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00002766 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →